The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia

Prenatal Diagnosis

Volumn 34, Issue 11, 2014, Pages 1084-1092

  Pinheiro, Cilene Carlos ^a,b   Rayol, Patricia ^b   Gozzani, Luiz ^b   dos Reis, Luciene Machado ^a   Zampieri, Gianfranco ^c   Dias, Cristiane Bitencourt ^a   Woronik, Viktoria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Maternity Hospital Santa Joana   (Brazil)

^c Laboratory of Clinical Pathology Salomão and Zoppi   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOGENIC FACTOR; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; GROWTH FACTOR RECEPTOR; HEMOGLOBIN; LACTATE DEHYDROGENASE; MAGNESIUM SULFATE; PLACENTAL GROWTH FACTOR; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; UREA; URIC ACID; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ADULT; APGAR SCORE; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DELIVERY; DISEASE SEVERITY; EARLY ONSET PREECLAMPSIA; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; LATE ONSET PREECLAMPSIA; LENGTH OF STAY; OXYGEN THERAPY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SMALL FOR DATE INFANT; STILLBIRTH; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; UREA BLOOD LEVEL; URINARY EXCRETION; BLOOD; NEWBORN; ONSET AGE; PRE-ECLAMPSIA; PREGNANCY; URINE;

ADULT; AGE OF ONSET; ANGIOGENESIS INDUCING AGENTS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84909951913     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4432     Document Type: Article

References (49)

1. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183(1):S1-22.
2. Duley L. The global impact of preeclampsia and eclampsia. Semin Perinatol 2009;33(3):130-7.
3. Laurenti R, Mello Jorge MHP, Gotlieb SLD. A mortalidade materna nas capitais brasileiras: algumas características e estimativa de um fator de ajuste. Rev Bras Epidemiol 2004;7(4):449-60.
4. Sibai BM. Editorial commentary: maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia. Hypertension 2008;52(5):805-6.
5. Moldenhauer JS, Stanek J, Warshak C, et al. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003;189(4):1173-7.
6. Noris M, Perico N, Remuzzi G. Mechanisms of disease: preeclampsia. Nat Clin Pract Nephrol 2005;1(2):98-114.
7. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obst Gynecol 2003;102(1):181-92.
8. Hauth JC, Ewell MNG, Levine RJ, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for preeclampsia prevention study group. Obst Gynecol 2000;95(1):24-8.
9. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001;97(4):533-8.
10. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125(7):911-9.
11. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009;200(5):481.e1-7.
12. Maynard SE, Min J-Y, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt 1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111(5):649-58.
13. Aggarwal PK, Jain V, Sakhuja V, et al. Low urinary placental growth factor is a marker of preeclampsia. Kidney Int 2006;69(3):621-4.
14. Maynard SE, Thadhani R. Pregnancy and the kidney. J Am Soc Nephrol 2009;20(1):14-22.
15. Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007;109(1):168-80.
16. Buhimschi CS, Norwitz ER, Funai E, et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005;192(3):734-41.
17. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350(7):672-83.
18. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190(6):1541-50.
19. Robinson CJ, Johnson DD, Chang EY, et al. Evaluation of placenta growth factor and soluble fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006;195:255-9.
20. Kim YN, Lee DS, Jeong DH, et al. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 2009;29:464-70.
21. Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293(1):77-85.
22. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PlGF ratio in assessment of preeclampsia. Am J Obstet Gynecol 2010;202(2):161.e1-11.
23. Schiettecatte J, Russcher H, Anckaert E, et al. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 2010;43(9):768-70.
24. Aydin S, Ersan F, Ark C, et al. Partial HELLP syndrome: maternal, perinatal, subsequent pregnancy and long-term maternal outcomes. J Obstet Gynaecol Res 2014;40(4): 932-40.
25. Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163-8.
26. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet 2005;365(9461):785-99.
27. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011;123(24):2856-69.
28. Sandrim VC, Palei ACT, Metzger IF, et al. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 2008;52(2):402-7.
29. Bridges JP, Gilbert JS, Colson D, et al. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 2009;22(5): 564-8.
30. Murphy SR, LaMarca BB, Cockrell K, et al. Role of endothelin in mediating soluble fms-like tyrosine kinase 1 - induced hypertension in pregnant rats. Hypertension 2010;55(2):394-8.
31. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206(1):58.e1-8.
32. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011;31(1):33-45.
33. Dwyer BK, Krieg S, Balise R, et al. Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia. J Matern Fetal Neonatal Med 2010;23(7):705-11.
34. Valenise H, Vasapollo B, Gagliardi G, et al. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension 2008;52(5):873-80.
35. Borzychowski AM, Sargent IL, Redman CWG. Inflammation and preeclampsia. Semin Fetal Neonatal Med 2006;11(5):309-16.
36. Chan P, Brown M, Simpson JM, et al. Proteinuria in preeclampsia: how much matters? BJOG 2005;112(3):280-5.
37. Newman MG, Robichaux AG, Stedman CM, et al. Perinatal outcomes in preeclampsia that is complicated by massive proteinuria. Am J Obstet Gynecol 2003;188(1):264-8.
38. Makris A, Thornton C, Thompson J, et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007;71(10):977-84.
39. Garovic VD, Wagner SJ, Turner ST, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007;196(4):320.e1-7.
40. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358(11):1129-36.
41. Henao DE, Saleem MA, Cadavid AP. Glomerular disturbances in preeclampsia: disruption between glomerular endothelium and podocyte symbiosis. Hypertens Pregnancy 2010;29(1):10-20.
42. Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors in early- vs late-onset preeclampsia and HELLP syndrome. J Perinat Med 2013;41(5):511-6.
43. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013;209(6):544.e1-e12.
44. Kucukgoz Gulec U, Ozgunen FT, Buyukkurt S, et al. Comparison of clinical and laboratory findings in early- and late-onset preeclampsia. J Matern Fetal Neonatal Med 2013;26(12):1228-33.
45. Veas CJ, Aguilera VC, Muñoz IJ, et al. Fetal endothelium dysfunction is associated with circulating maternal levels of sE-selectin, sVCAM1, and sFlt-1 during preeclampsia. J Matern Fetal Neonat Med 2011;24(11):1371-7.
46. Wallner W, Sengenberger R, Strick R, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci 2007;112:51-7.
47. Amarilyo G, Oren A, Mimouni FB, et al. Increased cord serum inflammatory markers in small-for-gestational-age neonates. J Perinatol 2011;31(1):30-2.
48. Catarino C, Santos-Silva A, Belo L, et al. Inflammatory disturbances in preeclampsia: relationship between maternal and umbilical cord blood. J Pregnancy 2012;2012:684384;10.
49. Ohkuchi A, Hirashima C, Suzuki H, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 2010;33(5):422-7.